Spyre Therapeutics, Inc. (SYRE): Total Liabilities
$62.55M
As of 2025-12-31
$71.86M
As of 2026-06-30
+44.2%
3-year compound annual growth
+23.5%
5-year compound annual growth
+37.7%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $62.55M | -31.0% | 2026-02-19, Balance as of period end |
| 2024-12-31 | $90.68M | +23.7% | 2026-02-19, Balance as of period end |
| 2023-12-31 | $73.29M | +251.7% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $20.84M | -19.8% | 2024-11-18, Balance as of period end |
| 2021-12-31 | $25.98M | +19.3% | 2023-03-02, Balance as of period end |
| 2020-12-31 | $21.79M | -5.7% | 2022-03-08, Balance as of period end |
| 2019-12-31 | $23.10M | +124.1% | 2021-03-18, Balance as of period end |
| 2018-12-31 | $10.31M | +79.6% | 2020-02-24, Balance as of period end |
| 2017-12-31 | $5.74M | +40.1% | 2019-03-07, Balance as of period end |
| 2016-12-31 | $4.10M | +60.7% | 2018-03-13, Balance as of period end |
| 2015-12-31 | $2.55M | n/a | 2017-03-23, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | 2025-12-31 | $62.55M | -31.0% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $71.53B | -6.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $10.78M | -5.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $121.39B | -2.8% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $117.67B | +8.3% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $99.59M | +24.7% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $7.00M | +0.4% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $3.14M | -44.7% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $241.54M | -9.5% |
Compare SYRE, BMY, TXMD, PFE side by side · Screen every company in Pharmaceutical Preparations ↗